ES2212127T3 - Utilizacion del factor angiogenico vegf145 en el tratamiento de las enfermedades cardiovasculares. - Google Patents

Utilizacion del factor angiogenico vegf145 en el tratamiento de las enfermedades cardiovasculares.

Info

Publication number
ES2212127T3
ES2212127T3 ES97940771T ES97940771T ES2212127T3 ES 2212127 T3 ES2212127 T3 ES 2212127T3 ES 97940771 T ES97940771 T ES 97940771T ES 97940771 T ES97940771 T ES 97940771T ES 2212127 T3 ES2212127 T3 ES 2212127T3
Authority
ES
Spain
Prior art keywords
vegf
new
protein product
treatment
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97940771T
Other languages
English (en)
Inventor
Gera Neufeld
Eli Keshet
Israel Vlodavsky
Zoya Poltorak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Collateral Therapeutics Inc
Original Assignee
Technion Research and Development Foundation Ltd
Collateral Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd, Collateral Therapeutics Inc filed Critical Technion Research and Development Foundation Ltd
Application granted granted Critical
Publication of ES2212127T3 publication Critical patent/ES2212127T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO PRODUCTO PROTEICO DE FACTOR DE CRECIMIENTO DEL ENDOTELIO VASCULAR (VEGF) Y UN ACIDO NUCLEICO QUE CODIFICA ESTE NUEVO PRODUCTO PROTEICO, QUE COMPRENDE UNOS EXONS 1-6 Y 8 DEL GEN VEGF, ASI COMO SU USO EN EL TRATAMIENTO DEL SISTEMA CARDIOVASCULAR Y DE SUS ENFERMEDADES POR EFECTOS SOBRE LA ANATOMIA, LA FUNCION VASCULAR Y LA PERMEABILIDAD. SE DESCUBRIO QUE EL VEGF ES UN MITOGENO ACTIVO PARA CELULAS ENDOTELIALES VASCULARES Y QUE ACTUABA COMO FACTOR ANGIOGENICO IN VIVO. EL VEGF 145 ESTA DOTADO DE NUEVAS PROPIEDADES CON RELACION A UNAS ESPECIES VEGF QUE SE CARACTERIZARON ANTERIORMENTE, EN CUANTO A LA DISTRIBUCION CELULAR, LA TENDENCIA A LOS DAÑOS OXIDATIVOS, Y LA CAPACIDAD DE ENLACE DE LA MATRIZ EXTRACELULAR (EM). LA PRESENTE INVENCION PREVE PROCEDIMIENTOS DESTINADOS A TRATAR EL SISTEMA CARDIOVASCULAR, A MEJORAR LA ENDOTELIALIZACION DE VASOS ENFERMOS Y A MEJORAR LA ASIMILACION DE MEDICAMENTOS MEDIANTE ESTE NUEVO PRODUCTO PROTEICO VEGF. LA PRESENTE INVENCION TAMBIEN PREVE VECTORES DE EXPRESION, COMPOSICIONES Y KITS A UTILIZAR EN LOS PROCEDIMIENTOS DE ESTA INVENCION
ES97940771T 1996-09-06 1997-09-04 Utilizacion del factor angiogenico vegf145 en el tratamiento de las enfermedades cardiovasculares. Expired - Lifetime ES2212127T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2553796P 1996-09-06 1996-09-06
US08/784,551 US6013780A (en) 1996-09-06 1997-01-21 VEGF145 expression vectors

Publications (1)

Publication Number Publication Date
ES2212127T3 true ES2212127T3 (es) 2004-07-16

Family

ID=26699889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97940771T Expired - Lifetime ES2212127T3 (es) 1996-09-06 1997-09-04 Utilizacion del factor angiogenico vegf145 en el tratamiento de las enfermedades cardiovasculares.

Country Status (14)

Country Link
US (3) US6013780A (es)
EP (1) EP0925360B1 (es)
JP (1) JP2001500728A (es)
KR (1) KR20000068506A (es)
CN (1) CN1236390A (es)
AT (1) ATE256186T1 (es)
AU (1) AU737898B2 (es)
CA (1) CA2265252C (es)
DE (1) DE69726741T2 (es)
EA (1) EA004646B1 (es)
ES (1) ES2212127T3 (es)
IL (1) IL128727A (es)
NZ (1) NZ334508A (es)
WO (1) WO1998010071A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
JP2002502608A (ja) * 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1126870B1 (en) * 1998-10-26 2004-09-08 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US20040131601A1 (en) * 2000-03-30 2004-07-08 Foundry Networks, Inc., A Delaward Corporation Injection of bone marrow-derived cells and medium for angiogenesis
US7097832B1 (en) 1999-03-30 2006-08-29 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2374050A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US6899731B2 (en) * 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
ATE362382T1 (de) * 2000-03-15 2007-06-15 Orbusneich Medical Inc Beschichtung welche ein anhaften von endothelzellen stimuliert
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
DK2277528T3 (en) 2000-04-12 2015-01-26 Vib Vzw Use of VEGF and homologs for treatment of neuronal diseases
CA2412847A1 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
CA2419245A1 (en) * 2000-08-17 2002-02-21 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US20050142130A1 (en) * 2001-01-04 2005-06-30 Roks Antonius J.M. Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
PL368972A1 (en) 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
JP2005502672A (ja) * 2001-08-29 2005-01-27 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
CA2487410C (en) * 2002-05-30 2015-03-24 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CN100398652C (zh) * 2002-12-09 2008-07-02 图尔金株式会社 调节性锌指蛋白
US20060252919A1 (en) * 2002-12-17 2006-11-09 Technion Research & Development Foundation Ltd. Vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR100772424B1 (ko) * 2005-08-05 2007-11-01 박기랑 ⅤＥＧＦ－Ａ，ⅤＥＧＦ－Ｂ，및 ⅤＥＧＦ－Ｃ의 안티센스 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스 및 ⅤＥＧＦＲ 트렁케이티드 솔루블 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스를 포함하는 암의 유전자 치료제
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2010042471A2 (en) * 2008-10-07 2010-04-15 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
CN110760542B (zh) * 2019-11-18 2022-07-26 天津大学 一种共表达znf580和vegf165双基因的质粒及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5288846A (en) * 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
ATE206756T1 (de) * 1994-07-20 2001-10-15 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von stabilisierter getrockeneter carboxyesterase
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors

Also Published As

Publication number Publication date
NZ334508A (en) 2001-03-30
AU4247197A (en) 1998-03-26
WO1998010071A1 (en) 1998-03-12
US6583276B1 (en) 2003-06-24
EA004646B1 (ru) 2004-06-24
EA199900262A1 (ru) 1999-10-28
CA2265252C (en) 2005-04-19
CA2265252A1 (en) 1998-03-12
US6013780A (en) 2000-01-11
HK1020756A1 (en) 2000-05-19
DE69726741T2 (de) 2004-09-30
EP0925360A1 (en) 1999-06-30
IL128727A (en) 2007-06-17
KR20000068506A (ko) 2000-11-25
CN1236390A (zh) 1999-11-24
US6589782B1 (en) 2003-07-08
JP2001500728A (ja) 2001-01-23
DE69726741D1 (de) 2004-01-22
IL128727A0 (en) 2005-11-20
AU737898B2 (en) 2001-09-06
ATE256186T1 (de) 2003-12-15
EP0925360B1 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
ES2212127T3 (es) Utilizacion del factor angiogenico vegf145 en el tratamiento de las enfermedades cardiovasculares.
ES2952050T3 (es) Composiciones de exosomas y métodos para su preparación y uso para la regulación y el acondicionamiento de la piel y el cabello
Maeng et al. Humanized skeletal muscle in MYF5/MYOD/MYF6-null pig embryos
Tatemoto et al. Protection of porcine oocytes against cell damage caused by oxidative stress during in vitro maturation: role of superoxide dismutase activity in porcine follicular fluid
Brevini et al. Role of adenosine triphosphate, active mitochondria, and microtubules in the acquisition of developmental competence of parthenogenetically activated pig oocytes
Rappolee et al. Developmental expression of PDGF, TGF-α, and TGF-β genes in preimplantation mouse embryos
Xie et al. Histone H3 lysine 27 trimethylation acts as an epigenetic barrier in porcine nuclear reprogramming
Lin et al. Melatonin supplementation during prolonged in vitro maturation improves the quality and development of poor‐quality porcine oocytes via anti‐oxidative and anti‐apoptotic effects
AR036827A1 (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas
ES2140542T3 (es) Celulas madre embrionarias para la obtencion de ungulados quimericos y transgenicos.
DE69942351D1 (de) Methoden und Reagenzien zur Erhaltung der RNA in Zellen und Geweben
ES2195998T3 (es) Sistemas de expresion de dna basados en alfavirus.
Léavesque et al. Effects of different kinases and phosphatases on nuclear and cytoplasmic maturation of bovine oocytes
Ranera et al. Expansion under hypoxic conditions enhances the chondrogenic potential of equine bone marrow-derived mesenchymal stem cells
Luo et al. The localization and expression of epidermal growth factor and epidermal growth factor receptor in bovine ovary during oestrous cycle
Niu et al. Nitric oxide-induced protein S-nitrosylation causes mitochondrial dysfunction and accelerates post-ovulatory aging of oocytes in cattle
Schwarz et al. Influence of nitric oxide during maturation on bovine oocyte meiosis and embryo development in vitro
Sonjaya et al. Effects of glutathione on oocyte and embryo development in in vitro fertilization
Salvetti et al. Structural, metabolic and developmental evaluation of ovulated rabbit oocytes before and after cryopreservation by vitrification and slow freezing
Javanshir et al. Induction of tenogenic differentiation of equine adipose-derived mesenchymal stem cells by platelet-derived growth factor-BB and growth differentiation factor-6
Labruijere et al. Analysis of the vascular responses in a murine model of polycystic ovary syndrome
Coleman et al. In vitro maturation and early developmental capacity of bovine oocytes cultured in pure follicular fluid and supplementation with follicular wall
Hosaka et al. Effect of heat on synthesis of gelatinases and pro-inflammatory cytokines in equine tendinocytes
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
Kim et al. Physiological and functional roles of neurotrophin-4 during in vitro maturation of porcine cumulus–oocyte complexes